About ELZONRIS®

ELZONRIS (tagraxofusp-erzs) is indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older.

Please See Full Prescribing Information, including Boxed Warning for Capillary Leak Syndrome

About ORSERDU™

ORSERDU (elacestrant) is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, HER2-negative, ESR-1 mutated advanced or metastatic breast cancer, following at least one line of endocrine therapy.

 

Learn More

Our Products & Pipeline

At Stemline, we are committed to applying our scientific leadership to transform the lives of people with cancer. We are focused on the development of a broad pipeline of innovative, transformative therapies in oncology.

 

Learn More

Stemline News & Media

Stemline is part of the Menarini Group, a leading international pharmaceutical and diagnostics company, with a turnover of over $4 billion and over 18,000 employees. Menarini is focused on therapeutic areas with high unmet needs with products for cardiology, oncology, pneumology, gastroenterology, infectious diseases, diabetology, inflammation, and analgesia.

Learn More